EB-1089, A NOVEL VITAMIN-D ANALOG, HAS STRONG ANTIPROLIFERATIVE AND DIFFERENTIATION-INDUCING EFFECTS ON CANCER-CELLS
EB-1089, A NOVEL VITAMIN-D ANALOG, HAS STRONG ANTIPROLIFERATIVE AND DIFFERENTIATION-INDUCING EFFECTS ON CANCER-CELLS
复制标题
DOI：
10.1016/0960-0760(93)90226-m
复制
发表时间：
1993-09-01
影响因子：
4.1
通讯作者：
BINDERUP, L
中科院分区：
文献类型：
--
作者：
MATHIASEN, IS;COLSTON, KW;BINDERUP, L
EB 1089是一种新的维生素D类似物，在体外对U937组织细胞淋巴瘤细胞和MCF-7乳腺癌细胞具有强烈的抑制作用，其效力是1，25-二羟基维生素D3[1，25(OH)2D3]的50~100倍。对MCF-7细胞c-myc、c-fos表达和U937细胞分化标志物的研究表明，EB 1089抑制细胞生长的同时伴有分化诱导。与1，25(OH)2D3相比，EB 1089对大鼠体内钙代谢的影响能力降低。这种低钙化作用与体外对癌细胞的强烈生物学作用相结合，使EB 1089成为治疗癌症的有趣候选药物。
EB 1089 is a novel vitamin D analogue which in vitro strongly inhibits the proliferation of U937 histiocytic lymphoma cells and MCF-7 breast cancer cells, with a potency of 50 to 100 times that of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. Studies of c-myc and c-fos expression in MCF-7 cells and of differentiation markers in U937 cells show that growth inhibition by EB 1089 is accompanied by induction of differentiation. The ability of EB 1089 to affect calcium metabolism in vivo in rats is decreased, compared to 1,25(OH)2D3. This low calcemic effect combined with the strong biological effect on cancer cells in vitro, makes EB 1089 an interesting candidate for treatment of cancer.